✨ Free AI Report
Evommune, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Evommune, Inc.
Company Research

Evommune, Inc.: Business Overview, Financials & Competitive Analysis

Evommune, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Clinical-stage inflammatory disease specialist with well-capitalized development program targeting large underserved patient populations in chronic inflammatory conditions. Early-stage biotech with recently completed IPO showing strong investor confidence ($150M raised). Two late-stage clinical programs in high-need inflammatory disease indications with significant market opportunity. However, clinical-stage status carries significant execution risk with.

What is Evommune, Inc.'s industry? Evommune, Inc. (evommune.com) operates in Clinical-Stage Biotechnology / Immunology & Inflammatory Diseases. AskCyborg classifies Evommune, Inc. under Clinical-Stage Biotechnology / Immunology & Inflammatory Diseases in its company registry.

Evommune is a clinical-stage biotechnology company in the United States that develops therapies targeting key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic sp...

7/ 10Strong

Cyborg Score thesis

Clinical-stage inflammatory disease specialist with well-capitalized development program targeting large underserved patient...

Read the full analyst-debate transcript →
Industry Clinical-Stage Biotechnology / Immunology & Inflammatory Diseases
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Evommune, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Evommune, Inc.

AskCyborg analysts argue the bull and bear cases for Evommune, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Evommune, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Evommune, Inc. Overview

Pro stress-test →

Evommune is a clinical-stage biotechnology company in the United States that develops therapies targeting key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. The company's mission is to improve patients' daily lives and prevent the long-term effects of uncontrolled inflammation.

Strategic Profile

Pro stress-test →

The company's product portfolio includes EVO756 for treating chronic spontaneous urticaria and atopic dermatitis, and EVO301 for treating atopic dermatitis and ulcerative colitis. Evommune completed its IPO on the NYSE in November 2025 via a $150 million offering to fund clinical-stage candidates.

Competitive Landscape

Pro stress-test →

Operates in competitive immunology/dermatology space alongside companies like MapLight Therapeutics and Apogee Therapeutics. Differentiated by focus on inflammatory disease drivers and dual-indication capability of lead assets. Limited direct competitors at clinical stage in this specific therapeutic niche.

Industry Context

Evommune, Inc. operates in Clinical-Stage Biotechnology / Immunology & Inflammatory Diseases.

Key facts

Founded: 2020 · Headquarters: Palo Alto, California · Market cap: $0.878B

What the analysts stress-tested

The top findings that survived the multi-agent debate for Evommune, Inc..

  • Completed successful IPO in November 2025 at $16/share, raising $150M for pipeline advancement
  • Focused two-asset strategy (EVO756 and EVO301) targeting high-prevalence inflammatory diseases with limited treatment options
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • November 2025IPO completion on NYSE at $16/share for $150 million gross proceeds
  • February 2026Stock surged 64-70% on positive clinical trial announcements
  • +1 moreTrack every material event for Evommune, Inc. as it happens. Explore monitoring →
Get alerted when Evommune, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Inflammatory disease programsClinical-stage biotech with $250M Nasdaq IPO; develops therapies for inflammatory conditions→Dermatology/immunology programsFocused on dermatology and immunology therapeutic solutions→

Compare Evommune, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Evommune, Inc. operates in Clinical-Stage Biotechnology / Immunology & Inflammatory Diseases. See how the rest of the sector scores on the Cyborg framework.

Top companies in Clinical-Stage Biotechnology by Cyborg Score

Browse Clinical-Stage Biotechnology / Immunology & Inflammatory Diseases research →
NEW · MCP server

Ask your AI assistant about Evommune, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Evommune, Inc. and its top competitor on Cyborg Score”
“What did Evommune, Inc. do this quarter?”
“Is Evommune, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Evommune, Inc. do?+
Evommune is a clinical-stage biotechnology company in the United States that develops therapies targeting key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic sp...
What is Evommune, Inc.'s Cyborg Score?+
Evommune, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Evommune, Inc.'s main competitors?+
Named competitors include Inflammatory disease programs, Dermatology/immunology programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Evommune, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Evommune, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Evommune, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Clinical-Stage Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Adaptive Biotechnologies Corporation7Monte Rosa Therapeutics, Inc.7PepGen Inc.7Tectonic Therapeutic, Inc.6Adlai Nortye Ltd.6Coya Therapeutics, Inc.6Vigil Neuroscience, Inc.5Cel-Sci Corporation4Cassava Sciences, Inc.4INmune Bio Inc.Top companies in Clinical-Stage Biotechnology by Cyborg Score